Charles River Laboratories International Inc Dossier
Qualitative Analysis
Business overview
Charles River Laboratories International, Inc. (NYSE: CRL) is a leading global non-clinical contract research organization (CRO) that provides essential products and services to help pharmaceutical and biotechnology companies, government agencies, and academic institutions accelerate their research and drug development efforts. Founded in 1947, the company operates through three primary segments: Research Models and Services (RMS), which is the global leader in breeding and delivering animal research models; Discovery and Safety Assessment (DSA), which provides early-stage development and safety testing services; and Manufacturing Solutions, which supports microbial testing, biologics testing, and specialized quality control services.
Research as of 19 Jun 2026
Strategic Initiatives
Growth programs, investments, and their expected impact
A dedicated initiative to develop and validate New Approach Methodologies (NAMs)—such as advanced in vitro models, organ-on-a-chip technologies, and computational approaches—to reduce reliance on traditional animal testing [2.1.2].
Expected impact: Aims to provide human-relevant data, uphold ethical commitments, and align with regulatory guidelines on AI and non-animal testing in drug development.
Shedding lower-margin, non-core, or underperforming assets, including the contract development and manufacturing organization (CDMO) and certain European discovery service assets.
Expected impact: Reduces reported annual revenue by slightly over $200 million but expands non-GAAP operating margins by 120 to 150 basis points and sharpens focus on core discovery and preclinical services.
Mergers, Acquisitions & Partnerships
Recent deals and strategic collaborations
Recent Acquisitions
To secure and safeguard the non-human primate (NHP) supply chain for the Discovery and Safety Assessment (DSA) segment, enabling internal sourcing of most future annual NHP requirements [2.4.4].
Financial impact: Expected to be accretive to non-GAAP EPS by approximately $0.25 in 2026 and $0.60 in 2027.
Acquisition of the remaining 79% equity stake to enhance next-generation sequencing (NGS) capabilities for rapid, in vitro manufacturing quality-control testing, supporting the company's NAMs goals.
Financial impact: Expected to generate annual revenue of approximately $15 to $20 million in 2026, with no material impact on 2026 or 2027 GAAP or non-GAAP financial results.
Strategic Partnerships
Fuses Charles River's nonclinical testing expertise with Eli Lilly's AI/ML models to accelerate drug discovery. Charles River will provide nonclinical testing services to TuneLab-associated biotech companies, standardizing testing protocols and enhancing federated learning models [2.1.3].
Terms: Participating biotech companies gain access to TuneLab's predictive models in exchange for data contributions, with Charles River acting as the preferred nonclinical testing partner.